Aminoglycosides: An overview

Cold Spring Harbor Perspectives in Medicine

Volumn 6, Issue 6, 2016, Pages

  Krause, Kevin M ^a   Serio, Alisa W ^a   Kane, Timothy R ^a   Connolly, Lynn E ^a,b  

^a Achaogen   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; GENTAMICIN; NETILMICIN; NUCLEOTIDYLTRANSFERASE; PAROMOMYCIN; PLAZOMICIN; RNA 16S; TOBRAMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; ELECTRON TRANSPORT; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; FRANCISELLA TULARENSIS; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; METHYLATION; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PROVIDENCIA; DRUG DESIGN; HUMAN; METABOLISM; MULTIDRUG RESISTANCE;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; RNA, RIBOSOMAL, 16S;

EID: 84973120195     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a027029     Document Type: Article

References (126)

1. Abis GS, Stockmann HB, van Egmond M, Bonjer HJ, Vandenbroucke-Grauls CM, Oosterling SJ. 2013. Selective decontamination of the digestive tract in gastrointestinal surgery: Useful in infection prevention? A systematic review. J Gastrointest Surg 17: 2172-2178.
2. Aggen JB, Armstrong ES, Goldblum AA, Dozzo P, Linsell MS, Gliedt MJ, Hildebrandt DJ, Feeney LA, Kubo A, Matias RD, et al. 2010. Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob Agents Chemother 54: 4636-4642.
3. Aínsa JA, Pérez E, Pelicic V, Berthet FX, Gicquel B, Martín C. 1997. Aminoglycoside 2ʹ-N-acetyltransferase genes are universally present in mycobacteria: Characterization of the aac(2ʹ)-Ic gene from Mycobacterium tuberculosis and the aac(2ʹ)-Id gene from Mycobacterium smegmatis. Mol Microbiol 24: 431-441.
4. Aires JR, Köhler T, Nikaido H, Plésiat P. 1999. Involvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob Agents Chemother 43: 2624-2628.
5. Almaghrabi R, Clancy CJ, Doi Y, Hao B, Chen L, Shields RK, Press EG, Iovine NM, Townsend BM, Wagener MM, et al. 2014. Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents. Antimicrob Agents Chemother 58: 4443-4451.
6. Al Sheikh YA, Marie MA, John J, Krishnappa LG, Dabwab KH. 2014. Prevalence of 16S rRNA methylase genes among b-lactamase-producing Enterobacteriaceae clinical isolates in Saudi Arabia. Libyan J Med 9: 24432.
7. American Thoracic Society; Infectious Diseases Society of America. 2005. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171: 388-416.
8. Armstrong ES, Miller GH. 2010. Combating evolution with intelligent design: The neoglycoside ACHN-490. Curr Opin Microbiol 13: 565-573.
9. Avent ML, Rogers BA, Cheng AC, Paterson DL. 2011. Current use of aminoglycosides: Indications, pharmacokinetics and monitoring for toxicity. Intern Med J 41: 441-449.
10. Azucena E, Mobashery S. 2001. Aminoglycoside-modifying enzymes: Mechanisms of catalytic processes and inhibition. Drug Resist Updat 4: 106-117.
11. Barclay ML, Kirkpatrick CM, Begg EJ. 1999. Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored? Clin Pharmacokinet 36: 89-98.
12. Beauclerk AA, Cundliffe E. 1987. Sites of action of two ribosomal RNA methylases responsible for resistance to aminoglycosides. J Mol Biol 193: 661-671.
13. Bell J, Andersson P, Jones R, Turnidge J. 2010. 16S rRNA methylase containing Enterobacteriaceae in the SENTRY Asia-Pacific region frequently harbour plasmid-mediated quinolone resistance CTXM types. 20th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Abstract O559. Vienna, April 10-13.
14. Ben Salah A, Ben Messaoud N, Guedri E, Zaatour A, Ben Alaya N, Bettaieb J, Gharbi A, Belhadj Hamida N, Boukthir A, Chlif S, et al. 2013. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. NEngl J Med 368: 524-532.
15. Benveniste R, Davies J. 1971. R-factor mediated gentamicin resistance: A new enzyme which modifies aminoglycoside antibiotics. FEBS Lett 14: 293-296.
16. Berçot B, Poirel L, Nordmann P. 2011. Updated multiplex polymerase chain reaction for detection of 16S rRNA methylases: High prevalence among NDM-1 producers. Diagn Microbiol Infect Dis 71: 442-445.
17. Bercovier H, Kafri O, Sela S. 1986. Mycobacteria possess a surprisingly small number of ribosomal RNA genes in relation to the size of their genome. Biochem Biophys Res Commun 136: 1136-1141.
18. Brogden RN, Pinder RM, Sawyer PR, Speight TM, Avery GS. 1976. Tobramycin: A review of its antibacterial and pharmacokinetic properties and therapeutic use. Drugs 12: 166-200.
19. Brooke JS. 2012. Stenotrophomonas maltophilia: An emerging global opportunistic pathogen. ClinMicrobiol Rev 25: 2-41.
20. Buijk SE, Mouton JW, Gyssens IC, Verbrugh HA, Bruining HA. 2002. Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med 28: 936-942.
21. Buroni S, Pasca MR, Flannagan RS, Bazzini S, Milano A, Bertani I, Venturi V, Valvano MA, Riccardi G. 2009. Assessment of three resistance-nodulation-cell division drug efflux transporters of Burkholderia cenocepacia in intrinsic antibiotic resistance. BMC Microbiol 9: 200.
22. Castanheira M, Costello SE, Jones RN, Mendes RE. 2015. Prevalence of aminoglycoside resistance genes among contemporary Gram-negative resistant isolates collected worldwide. 25th European Congress of Clinical Microbriology and Infectious Diseases (ECCMID), Abstract O011. Copenhagen, April 25-28.
23. Cattoir V, Nordmann P. 2009. Plasmid-mediated quinolone resistance in Gram-negative bacterial species: An update. Curr Med Chem 16: 1028-1046.
24. Costa Y, Galimand M, Leclercq R, Duval J, Courvalin P. 1993. Characterization of the chromosomal aac(6ʹ)-Ii gene specific for Enterococcus faecium. Antimicrob Agents Chemother 37: 1896-1903.
25. Courvalin P. 1994. Transfer of antibiotic resistance genes between Gram-positive and Gram-negative bacteria. Antimicrob Agents Chemother 38: 1447-1451.
26. Craig WA. 2011. Optimizing aminoglycoside use. Crit Care Clin 27: 107-121.
27. Craig WA, Redington J, Ebert SC. 1991. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother 27: 29-40.
28. Culebras E, Martínez JL. 1999. Aminoglycoside resistance mediated by the bifunctional enzyme 6ʹ-N-aminoglycoside acetyltransferase-2ʺ-O-aminoglycoside phosphotransferase. Front Biosci 4: D1-D8.
29. Cundliffe E. 1989. How antibiotic-producing organisms avoid suicide. Annu Rev Microbiol 43: 207-233.
30. Daneman N, Sarwar S, Fowler RA, Cuthbertson BH, Group SCS. 2013. Effect of selective decontamination on antimicrobial resistance in intensive care units: A systematic review and meta-analysis. Lancet Infect Dis 13: 328-341.
31. Davis BD. 1987. Mechanism of bactericidal action of aminoglycosides. Microbiol Rev 51: 341-350.
32. Davis BD, Chen LL, Tai PC. 1986. Misread protein creates membrane channels: An essential step in the bactericidal action of aminoglycosides. Proc Natl Acad Sci 83: 6164-6168.
33. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, et al. 2013. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 41: 580-637.
34. Dennis DT, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Friedlander AM, Hauer J, Layton M, et al. 2001. Tularemia as a biological weapon:Medical and public health management. JAMA 285: 2763-2773.
35. Doi Y, Yokoyama K, Yamane K, Wachino J, Shibata N, Yagi T, Shibayama K, Kato H, Arakawa Y. 2004. Plasmid-mediated 16S rRNA methylase in Serratia marcescens conferring high-level resistance to aminoglycosides. Antimicrob Agents Chemother 48: 491-496.
36. Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A. 2007. Back to the future: Using aminoglycosides again and how to dose them optimally. Clin Infect Dis 45: 753-760.
37. Dzidic S, Bedeković V. 2003. Horizontal gene transferemerging multidrug resistance in hospital bacteria. Acta Pharmacol Sin 24: 519-526.
38. Eliopoulos GM, Eliopoulos CT. 1988. Antibiotic combinations: Should they be tested? Clin Microbiol Rev 1: 139-156.
39. Falagas ME, Siempos II, Bliziotis IA, Michalopoulos A. 2006. Administration of antibiotics via the respiratory tract for the prevention of ICU-acquired pneumonia: A meta-analysis of comparative trials. Crit Care 10: R123.
40. Feizabadi MM, Asadi S, Zohari M, Gharavi S, Etemadi G. 2004. Genetic characterization of high-level gentamicinresistant strains of Enterococcus faecalis in Iran. Can J Microbiol 50: 869-872.
41. Gonzalez-Padilla M, Torre-Cisneros J, Rivera-Espinar F, Pontes-Moreno A, López-Cerero L, Pascual A, Natera C, Rodríguez M, Salcedo I, Rodríguez-Ló pez F, et al. 2015. Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae. J Antimicrob Chemother 70: 905-913.
42. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, et al. 2007. An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175: 367-416.
43. Hancock RE. 1984. Alterations in outer membrane permeability. Annu Rev Microbiol 38: 237-264.
44. Hancock RE, Raffle VJ, Nicas TI. 1981. Involvement of the outer membrane in gentamicin and streptomycin uptake and killing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 19: 777-785.
45. Hancock RE, Farmer SW, Li ZS, Poole K. 1991. Interaction of aminoglycosides with the outer membranes and purified lipopolysaccharide and OmpF porin of Escherichia coli. Antimicrob Agents Chemother 35: 1309-1314.
46. Ho YI, Chan CY, Cheng AF. 1997. In-vitro activities of aminoglycoside-aminocyclitols againstmycobacteria. J Antimicrob Chemother 40: 27-32.
47. Hocquet D, Vogne C, El Garch F, Vejux A, Gotoh N, Lee A, Lomovskaya O, Plésiat P. 2003. MexXY-OprM efflux pump is necessary for adaptive resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob Agents Chemother 47: 1371-1375.
48. Hollingshead S, Vapnek D. 1985. Nucleotide sequence analysis of a gene encoding a streptomycin/spectinomycin adenylyltransferase. Plasmid 13: 17-30.
49. Humes HD, Weinberg JM, Knauss TC. 1982. Clinical and pathophysiologic aspects of aminoglycoside nephrotoxicity. Am J Kidney Dis 2: 5-29.
50. Ikäheimo I, Syrjälä H, Karhukorpi J, Schildt R, Koskela M. 2000. In vitro antibiotic susceptibility of Francisella tularensis isolated from humans and animals. J Antimicrob Chemother 46: 287-290.
51. Ioannidou E, Siempos II, Falagas ME. 2007. Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: A metaanalysis. J Antimicrob Chemother 60: 1216-1226.
52. Islam S, Jalal S, Wretlind B. 2004. Expression of the MexXY efflux pump in amikacin-resistant isolates of Pseudomonas aeruginosa. Clin Microbiol Infect 10: 877-883.
53. Jackson J, Chen C, Buising K. 2013. Aminoglycosides: How should we use them in the 21st century? Curr Opin Infect Dis 26: 516-525.
54. Jones RN, Flonta M, Gurler N, Cepparulo M, Mendes RE, Castanheira M. 2014. Resistance surveillance program report for selected European nations (2011). Diagn Microbiol Infect Dis 78: 429-436.
55. Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF. 2003. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother 47: 1681-1688.
56. Kim C, Mobashery S. 2005. Phosphoryl transfer by aminoglycoside 30-phosphotransferases and manifestation of antibiotic resistance. Bioorg Chem 33: 149-158.
57. Kislak JW. 1972. The susceptibility of Bacteroides fragilis to 24 antibiotics. J Infect Dis 125: 295-299.
58. Kotra LP, Haddad J, Mobashery S. 2000. Aminoglycosides: Perspectives on mechanisms of action and resistance and strategies to counter resistance. Antimicrob Agents Chemother 44: 3249-3256.
59. Landman D, Babu E, Shah N, Kelly P, Bäcker M, Bratu S, Quale J. 2010. Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City. J Antimicrob Chemother 65: 2123-2127.
60. Landman D, Kelly P, Bäcker M, Babu E, Shah N, Bratu S, Quale J. 2011. Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City. J Antimicrob Chemother 66: 332-334.
61. Le J, McKee B, Srisupha-Olarn W, Burgess DS. 2011. In vitro activity of carbapenems alone and in combination with amikacin against KPC-producing Klebsiella pneumoniae. J Clin Med Res 3: 106-110.
62. Le Goffic F, Baca B, Soussy CJ, Dublanchet A, Duval J. 1976. ANT(4ʹ)I: A new aminoglycoside nucleotidyltransferase found in “staphylococcus aureus. ” Ann Microbiol (Paris) 127: 391-399 (author’s transl.)
63. Livermore DM, Mushtaq S, Warner M, Zhang JC, Maharjan S, Doumith M, Woodford N. 2011. Activity of aminoglycosides, including ACHN-490, against carbapenemresistant Enterobacteriaceae isolates. J Antimicrob Chemother 66: 48-53.
64. Llano-Sotelo B, Azucena EF, Kotra LP, Mobashery S, Chow CS. 2002. Aminoglycosides modified by resistance enzymes display diminished binding to the bacterial ribosomal aminoacyl-tRNA site. Chem Biol 9: 455-463.
65. Lode H, Grunert K, Koeppe P, Langmaack H. 1976. Pharmacokinetic and clinical studies with amikacin, a new aminoglycoside antibiotic. J Infect Dis 134: S316-S322.
66. Macinga DR, Rather PN. 1999. The chromosomal 20-Nacetyltransferase of Providencia stuartii: Physiological functions and genetic regulation. Front Biosci 4: D132-D140.
67. Magnet S, Blanchard JS. 2005. Molecular insights into aminoglycoside action and resistance. Chem Rev 105: 477-498.
68. Magnet S, Courvalin P, Lambert T. 2001. Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrob Agents Chemother 45: 3375-3380.
69. Martin WJ, Gardner M, Washington JA. 1972. In vitro antimicrobial susceptibility of anaerobic bacteria isolated from clinical specimens. Antimicrob Agents Chemother 1: 148-158.
70. Matsumoto T. 2014. Arbekacin: Another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens. Clin Pharmacol 6: 139-148.
71. Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. 1999. Aminoglycosides: Activity and resistance. Antimicrob Agents Chemother 43: 727-737.
72. Miró E, Grünbaum F, Gómez L, Rivera A, Mirelis B, Coll P, Navarro F. 2013. Characterization of aminoglycosidemodifying enzymes in enterobacteriaceae clinical strains and characterization of the plasmids implicated in their diffusion. Microb Drug Resist 19: 94-99.
73. Moore RD, Smith CR, Lipsky JJ, Mellits ED, Lietman PS. 1984. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 100: 352-357.
74. Murphy E. 1985. Nucleotide sequence of a spectinomycin adenyltransferase AAD(9) determinant from Staphylococcus aureus and its relationship to AAD(3ʺ)(9). Mol Gen Genet 200: 33-39.
75. Murry KR, McKinnon PS, Mitrzyk B, Rybak MJ. 1999. Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside. Pharmacotherapy 19: 1252-1260.
76. Mushtaq S, Irfan S, Sarma JB, Doumith M, Pike R, Pitout J, Livermore DM, Woodford N. 2011. Phylogenetic diversity of Escherichia coli strains producing NDMtype carbapenemases. J Antimicrob Chemother 66: 2002-2005.
77. Mwengee W, Butler T, Mgema S, Mhina G, Almasi Y, Bradley C, Formanik JB, Rochester CG. 2006. Treatment of plague with gentamicin or doxycycline in a randomized clinical trial in Tanzania. Clin Infect Dis 42: 614-621.
78. Nagabhushan T, Miller G, Weinstein M. 1982. Structure-activity relationships in aminoglycoside-aminocyclitol antibiotics. In The aminoglycosides: Microbiology, clinical use and toxicology (ed. Whelton A, Neu HC), pp. 3-27. Marcel Dekker, New York.
79. Nichols WW, Young SN. 1985. Respiration-dependent uptake of dihydrostreptomycin by Escherichia coli. Its irreversible nature and lack of evidence for a uniport process. Biochem J 228: 505-512.
80. Nicolau DP, Belliveau PP, Nightingale CH, Quintiliani R, Freeman CD. 1995. Implementation of a once-daily aminoglycoside program in a large community-teaching hospital. Hosp Pharm 30: 674-676, 679-680.
81. Okamoto S, Suzuki Y. 1965. Chloramphenicol-, dihydrostreptomycin-, and kanamycin-inactivating enzymes from multiple drug-resistant Escherichia coli carrying episome “R”. Nature 208: 1301-1303.
82. Ounissi H, Derlot E, Carlier C, Courvalin P. 1990. Gene homogeneity for aminoglycoside-modifying enzymes in Gram-positive cocci. Antimicrob Agents Chemother 34: 2164-2168.
83. Pankuch GA, Seifert H, Appelbaum PC. 2010. Activity of doripenem with and without levofloxacin, amikacin, and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii. Diagn Microbiol Infect Dis 67: 191-197.
84. Plantinga NL, Bonten MJ. 2015. Selective decontamination and antibiotic resistance in ICUs. Crit Care 19: 259.
85. Podnecky NL, Rhodes KA, Schweizer HP. 2015. Efflux pump-mediated drug resistance in Burkholderia. Front Microbiol 6: 305
86. Poirel L, Savov E, Nazli A, Trifonova A, Todorova I, Gergova I, Nordmann P. 2014. Outbreak caused by NDM-1-and RmtB-producing Escherichia coli in Bulgaria. Antimicrob Agents Chemother 58: 2472-2474
87. Price R, MacLennan G, Glen J; SuDDICU Collaboration. 2014. Selective digestive or oropharyngeal decontamination and topical oropharyngeal chlorhexidine for prevention of death in general intensive care: Systematic review and network meta-analysis. BMJ 348: g2197.
88. Prins JM, Büller HR, Kuijper EJ, Tange RA, Speelman P. 1993. Once versus thrice daily gentamicin in patients with serious infections. Lancet 341: 335-339.
89. Ramirez MS, Tolmasky ME. 2010. Aminoglycoside modifying enzymes. Drug Resist Updat 13: 151-171.
90. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, et al. 1999. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 340: 23-30.
91. Rather PN, Orosz E, Shaw KJ, Hare R, Miller G. 1993. Characterization and transcriptional regulation of the 20-N-acetyltransferase gene from Providencia stuartii. J Bacteriol 175: 6492-6498.
92. Ristuccia AM, Cunha BA. 1985. An overview of amikacin. Ther Drug Monit 7: 12-25.
93. Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC. 2006. Fluoroquinolone-modifying enzyme: A new adaptation of a common aminoglycoside acetyltransferase. Nat Med 12: 83-88.
94. Roos D, Dijksman LM, Tijssen JG, Gouma DJ, Gerhards MF, Oudemans-van Straaten HM. 2013. Systematic review of perioperative selective decontamination of the digestive tract in elective gastrointestinal surgery. Br J Surg 100: 1579-1588.
95. Rosenberg EY, Ma D, Nikaido H. 2000. AcrD of Escherichia coli is an aminoglycoside efflux pump. J Bacteriol 182: 1754-1756.
96. Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. 1999. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 43: 1549-1555.
97. Sader HS, Farrell DJ, Flamm RK, Jones RN. 2014. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in U. S. and European hospitals: Results from the SENTRYAntimicrobial Surveillance Program, 2009-2012. Int J Antimicrob Agents 43: 328-334.
98. Sader HS, Rhomberg PR, Farrell DJ, Jones RN. 2015. Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia. Antimicrob Agents Chemother 59: 3263-3270.
99. Sawicki GS, Signorovitch JE, Zhang J, Latremouille-Viau D, vonWartburg M, Wu EQ, Shi L. 2012. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Pediatr Pulmonol 47: 44-52.
100. Schwartz JJ, Gazumyan A, Schwartz I. 1992. rRNA gene organization in the Lyme disease spirochete, Borrelia burgdorferi. J Bacteriol 174: 3757-3765.
101. Shaw KJ, Rather PN, Hare RS, Miller GH. 1993. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev 57: 138-163.
102. Simon VK, Mösinger EU, Malerczy V. 1973. Pharmacokinetic studies of tobramycin and gentamicin. Antimicrob Agents Chemother 3: 445-450.
103. Skeggs PA, Thompson J, Cundliffe E. 1985. Methylation of 16S ribosomal RNA and resistance to aminoglycoside antibiotics in clones of Streptomyces lividans carrying DNA from Streptomyces tenjimariensis. Mol Gen Genet 200: 415-421.
104. Snowden J, Stovall S. 2011. Tularemia: Retrospective review of 10 years’ experience in Arkansas. Clin Pediatr (Phila) 50: 64-68.
105. Stover KR, Riche DM, Gandy CL, Henderson H. 2012. What would we do without metronidazole? Am J Med Sci 343: 316-319.
106. Strahilevitz J, Jacoby GA, Hooper DC, Robicsek A. 2009. Plasmid-mediated quinolone resistance: A multifaceted threat. Clin Microbiol Rev 22: 664-689.
107. Stubbings W, Bostock J, Ingham E, Chopra I. 2006. Mechanisms of the post-antibiotic effects induced by rifampicin and gentamicin in Escherichia coli. J Antimicrob Chemother 58: 444-448.
108. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. 2007. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 356: 2571-2581.
109. Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, et al. 2011. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: An open-label, non-inferiority, randomised controlled trial. Lancet 377: 477-486.
110. Swenson JM, Wallace RJ, Silcox VA, Thornsberry C. 1985. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother 28: 807-811.
111. Taber HW, Mueller JP, Miller PF, Arrow AS. 1987. Bacterial uptake of aminoglycoside antibiotics. Microbiol Rev 51: 439-457.
112. Tamma PD, Cosgrove SE, Maragakis LL. 2012. Combination therapy for treatment of infections with Gram-negative bacteria. Clin Microbiol Rev 25: 450-470.
113. Thompson J, Skeggs PA, Cundliffe E. 1985. Methylation of 16S ribosomal RNA and resistance to the aminoglycoside antibiotics gentamicin and kanamycin determined by DNA from the gentamicin-producer, Micromonospora purpurea. Mol Gen Genet 201: 168-173.
114. Vakulenko SB, Mobashery S. 2003. Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev 16: 430-450.
115. Wachino J, Arakawa Y. 2012. Exogenously acquired 16S rRNA methyltransferases found in aminoglycoside-resistant pathogenic Gram-negative bacteria: An update. Drug Resist Updat 15: 133-148.
116. Wachino J, Yamane K, Shibayama K, Kurokawa H, Shibata N, Suzuki S, Doi Y, Kimura K, Ike Y, Arakawa Y. 2006. Novel plasmid-mediated 16S rRNA methylase, RmtC, found in a Proteus mirabilis isolate demonstrating extraordinary high-level resistance against various aminoglycosides. Antimicrob Agents Chemother 50: 178-184.
117. Wachino J, Shibayama K, Kurokawa H, Kimura K, Yamane K, Suzuki S, Shibata N, Ike Y, Arakawa Y. 2007. Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides. Antimicrob Agents Chemother 51: 4401-4409.
118. Waters VL. 1999. Conjugative transfer in the dissemination of β-lactam and aminoglycoside resistance. Front Biosci 4: D433-D456.
119. Westbrock-Wadman S, Sherman DR, Hickey MJ, Coulter SN, Zhu YQ, Warrener P, Nguyen LY, Shawar RM, Folger KR, Stover CK. 1999. Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability. Antimicrob Agents Chemother 43: 2975-2983.
120. Wilson DN. 2014. Ribosome-targeting antibiotics and mechanisms of bacterial resistance. Nat Rev Microbiol 12: 35-48.
121. World Health Organization. 2011. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. World Health Organization, Geneva.
122. Wright GD, Thompson PR. 1999. Aminoglycoside phosphotransferases: Proteins, structure, and mechanism. Front Biosci 4: D9-D21.
123. Yamane K, Wachino J, Doi Y, Kurokawa H, Arakawa Y. 2005. Global spread of multiple aminoglycoside resistance genes. Emerg Infect Dis 11: 951-953.
124. Yan JJ, Wu JJ, Ko WC, Tsai SH, Chuang CL, Wu HM, Lu YJ, Li JD. 2004. Plasmid-mediated 16S rRNA methylases conferring high-level aminoglycoside resistance in Escherichia coli and Klebsiella pneumoniae isolates from two Taiwanese hospitals. J Antimicrob Chemother 54: 1007-1012.
125. Yokoyama K, Doi Y, Yamane K, Kurokawa H, Shibata N, Shibayama K, Yagi T, Kato H, Arakawa Y. 2003. Acquisition of 16S rRNA methylase gene in Pseudomonas aeruginosa. Lancet 362: 1888-1893.
126. Zhanel GG, Hoban DJ, Harding GK. 1991. The postantibiotic effect: A review of in vitro and in vivo data. DICP 25: 153-163.